Overview

Low-Dose Oral Imatinib for Scleroderma Pulmonary Involvement

Status:
Unknown status
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to verify effect and tolerability of imatinib on pulmonary and skin fibrosis in patients affected by systemic sclerosis.
Phase:
Phase 2
Details
Lead Sponsor:
Azienda Ospedaliera Universitaria Policlinico
Collaborator:
Università Politecnica delle Marche
Treatments:
Imatinib Mesylate